UNITED STATES SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K
                                 CURRENT REPORT

     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
                        Date of Report: May 19, 2014


                           PEPTIDE TECHNOLOGIES, INC.
                           --------------------------
             (Exact name of registrant as specified in its charter)


    Nevada                          333-133347                   98-0479983
  (State or other            (Commission File Number)      (IRS Employer Number)
   jurisdiction of
   incorporation)

    601 Union Street, Two Union Square, 42nd Floor, Seattle, Washington 98101
    -------------------------------------------------------------------------
               (Address of Principal Executive Offices) (Zip Code)

                                 (206) 388-5498
                                 --------------
               Registrant's telephone number, including area code

Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)

[ ] Soliciting  material  pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))







                SECTION 1 - REGISTRANT'S BUSINESS AND OPERATIONS

Item 1.01 Entry into a Material Definitive Agreement

On December  11,  2012,  the  Company  formally  engaged  BB&T  Capital  Markets
("BB&TCM")  to act as the  Company's  exclusive  financial  advisor and agent in
connection with developing strategic alternatives for the Company regarding debt
financings,  licensing  of  intellectual  properties  developed  by the Company,
equity  raises,  sale of  intellectual  properties,  or  other  capital  markets
transactions that may develop over the course of a 24 month agreement.

On May 19, 2014,  the Company  renewed/extended  the Agreement with BB&T Capital
Markets.  The  extension  runs from May 1, 2014 through May 1, 2016 (24 months).
All other provisions of the Agreement remain unchanged.







                                   SIGNATURES

Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
Registrant  has duly  caused  this  Report  to be  signed  on its  behalf by the
undersigned, hereunto duly authorized.

                                             PEPTIDE TECHNOLOGIES, INC.



                                             By: /s/ J. Erik Odeen
                                                 -------------------------------
                                                 J. Erik Odeen
                                                 CFO
Date: May 19, 201